JP2005508318A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508318A5
JP2005508318A5 JP2003528493A JP2003528493A JP2005508318A5 JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5 JP 2003528493 A JP2003528493 A JP 2003528493A JP 2003528493 A JP2003528493 A JP 2003528493A JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003528493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508318A (ja
JP4269052B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/029232 external-priority patent/WO2003024395A2/en
Publication of JP2005508318A publication Critical patent/JP2005508318A/ja
Publication of JP2005508318A5 publication Critical patent/JP2005508318A5/ja
Application granted granted Critical
Publication of JP4269052B2 publication Critical patent/JP4269052B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003528493A 2001-09-14 2002-09-13 連結ビアリール化合物 Expired - Fee Related JP4269052B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32255601P 2001-09-14 2001-09-14
US33543401P 2001-11-30 2001-11-30
US37862702P 2002-05-07 2002-05-07
US38683302P 2002-06-06 2002-06-06
PCT/US2002/029232 WO2003024395A2 (en) 2001-09-14 2002-09-13 Linked biaryl compounds

Publications (3)

Publication Number Publication Date
JP2005508318A JP2005508318A (ja) 2005-03-31
JP2005508318A5 true JP2005508318A5 (show.php) 2006-01-05
JP4269052B2 JP4269052B2 (ja) 2009-05-27

Family

ID=27502245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528493A Expired - Fee Related JP4269052B2 (ja) 2001-09-14 2002-09-13 連結ビアリール化合物

Country Status (13)

Country Link
US (2) US6869975B2 (show.php)
EP (1) EP1435946B8 (show.php)
JP (1) JP4269052B2 (show.php)
KR (1) KR20040063897A (show.php)
CN (1) CN1585638A (show.php)
AU (1) AU2002336532C1 (show.php)
BR (1) BR0212512A (show.php)
CA (1) CA2460313C (show.php)
ES (1) ES2443642T3 (show.php)
IL (1) IL160845A0 (show.php)
MX (1) MXPA04002330A (show.php)
NZ (1) NZ531917A (show.php)
WO (1) WO2003024395A2 (show.php)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
CA2460313C (en) 2001-09-14 2011-03-08 Tularik Inc. Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004080283A2 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2005012221A1 (ja) * 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
ATE486055T1 (de) * 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US20110039841A1 (en) * 2004-05-05 2011-02-17 Novo Nordisk A/S Novel compounds, their preparation and use
ATE515494T1 (de) * 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
AU2005272786B2 (en) * 2004-08-12 2011-12-22 Amgen Inc. Bisaryl-sulfonamides
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
EP1819673A2 (en) * 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
JP2008521831A (ja) * 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
FR2880886B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005020230A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
DE102005020229A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
US20090118337A1 (en) * 2005-06-03 2009-05-07 Davis Pamela B Methods and compositions for treating inflammation
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
WO2007013694A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2009507846A (ja) * 2005-09-07 2009-02-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
US20080234349A1 (en) * 2005-09-07 2008-09-25 Jack Lin PPAR active compounds
RU2419618C2 (ru) * 2005-09-07 2011-05-27 Плекссикон, Инк. Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
WO2007071766A2 (en) 2005-12-22 2007-06-28 Transtech Pharma Phenoxy acetic acids as ppar delta activators
DK1976828T3 (en) 2005-12-29 2017-03-06 Celtaxsys Inc DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE
CA2645719A1 (en) * 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
US9486441B2 (en) 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2521713A4 (en) * 2010-01-06 2013-10-02 Panmira Pharmaceuticals Llc ANTAGONIST OF DP2 AND ITS USES
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR20150075120A (ko) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
JP6534650B2 (ja) 2013-03-14 2019-06-26 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
CN113912547B (zh) * 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
US11267795B2 (en) 2020-07-22 2022-03-08 Reneo Pharmaceuticals, Inc. Crystalline PPAR-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038934A (en) * 1959-03-17 1962-06-12 Smith Kline French Lab Iodinated 4-(4'-alkoxyphenoxy)phenylpropionic acids
US4443536A (en) * 1981-08-25 1984-04-17 Eastman Kodak Company Nondiffusible photographic couplers and photographic elements and processes employing same
US4466902A (en) 1982-01-31 1984-08-21 Ipposha Oil Industries, Co., Ltd. Rust inhibitor
DE68923591T2 (de) * 1988-09-14 1996-03-28 Eastman Kodak Co Photographisches Aufzeichnungsmaterial mit Magenta-Kuppler und einem Chalcogenazoliumsalz.
CA2194169A1 (en) 1994-07-01 1996-01-18 Ronald M. Evans Mammalian peroxisome proliferator-activated receptors and uses thereof
DE69728267T2 (de) 1996-02-02 2005-02-24 Merck & Co., Inc. Antidiabetisches mittel
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
AU708055B2 (en) 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
KR20010005632A (ko) * 1997-03-27 2001-01-15 우에하라 아끼라 2-페녹시아닐린 유도체
ATE421336T1 (de) 1997-07-24 2009-02-15 Astellas Pharma Inc Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
CA2315629A1 (en) 1997-12-23 1999-07-08 Mary Rodopoulos Boronic compounds
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6200995B1 (en) * 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
EP1101755B1 (en) * 1998-07-24 2004-10-06 Teijin Limited Anthranilic acid derivatives
EP1185230A1 (en) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
CA2377309C (en) 1999-06-30 2010-11-23 Tularik Inc. Compounds for the modulation of ppar.gamma. activity
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
ATE260912T1 (de) 1999-09-08 2004-03-15 Glaxo Group Ltd Oxazol ppar antagonisten
JP2003523336A (ja) 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
CZ302982B6 (cs) 2000-06-28 2012-02-01 Amgen Inc. 3-Chinolinylfenylsulfonamidová sloucenina, tato sloucenina pro použití jako lécivo a použití této slouceniny pri výrobe léciva
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
ATE542805T1 (de) 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
GB0024362D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU2002243778A1 (en) 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
ES2328795T3 (es) * 2001-02-14 2009-11-18 Karo Bio Ab Moduladores del receptor glucocorticoide.
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
EP1371650A4 (en) 2001-03-23 2005-05-04 Nippon Chemiphar Co ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS
CA2449515A1 (en) * 2001-08-24 2003-03-06 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
CA2460313C (en) * 2001-09-14 2011-03-08 Tularik Inc. Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels
US6960692B2 (en) * 2001-09-27 2005-11-01 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
US7230031B2 (en) * 2002-01-30 2007-06-12 Kissei Pharmaceutical Co., Ltd. Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Similar Documents

Publication Publication Date Title
JP2005508318A5 (show.php)
CA2460313A1 (en) Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels
TWI339121B (en) 1-piperazine- and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic application thereof
CN102030700B (zh) 苯甲酰胺基羧酸类化合物及其制法和药物用途
US5606073A (en) Diazole-propenoic acid compounds
SG192439A1 (en) Organic compounds
TW200523250A (en) Compounds for inflammation and immune-related uses
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
CN101163504A (zh) 联合疗法
TW200815422A (en) Heteroaryl derivatives as cytokine inhibitors
JP2009513703A5 (show.php)
JP2004529161A5 (show.php)
TW200901996A (en) Inhibitors of focal adhesion kinase
CN109641843A (zh) 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮
CN111285829A (zh) 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途
WO2010069124A1 (zh) 酰胺基噻唑衍生物及其制备方法和用途
CN109111426A (zh) 一类稠合双环杂芳基或芳基化合物，及其用途
JPWO2015199234A1 (ja) ハロゲン置換へテロ環化合物の塩
AU2015336458A1 (en) KCNQ2-5 channel activator
CN101068784A (zh) 间烟碱化合物的羟基苯甲酸盐
CN108727295A (zh) 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
JP2010531322A (ja) アントラニルアミドピリジンウレア及びベンズアミド誘導体の相乗組合せ
JPWO2001036402A1 (ja) 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP2009506127A (ja) 糖尿病の処置に有用なアニリノピラゾール誘導体
CN112739680A (zh) Dp拮抗剂